Literature DB >> 6407768

Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.

F Ambrosch, G Wiedermann, P Crooy, A M George.   

Abstract

A new tetravalent meningococcal polysaccharide vaccine containing groups A, C, W 135, and Y was administered to 40 healthy adults. The vaccine was well tolerated and bactericidal assay showed mean titre increases for the meningococcal polysaccharide groups A, C, W 135, and Y of 5.0, 7.8, 8.2, and 5.9 log(2) titre steps, respectively. The immunogenicity and side-effects of the vaccine were similar to those associated with monovalent and bivalent vaccines containing group A and C meningococcal polysaccharides.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6407768      PMCID： PMC2536123     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  25 in total

1.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

2.  Immunogenicity of the group A and group C meningococcal polysaccharides in children.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

3.  Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

Authors:  R Gold; M L Lepow; I Goldschneider; T L Draper; E C Gotschlich
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

4.  Meningococcal infections. 4. Stability of group A and group C polysaccharide vaccines.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

5.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

7.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

Authors:  M H Wahdan; F Rizk; A M el-Akkad; A A el-Ghoroury; R Hablas; N I Girgis; A Amer; W Boctar; J E Sippel; E C Gotschlich; R Triau; W R Sanborn; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

8.  Immunogenicity of group A and group C meningococcal polysaccharides in human infants.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich; F T Mauck; F Bachl; M Randolph
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

9.  A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.

Authors:  H H Erwa; M A Haseeb; A A Idris; L Lapeyssonnie; W R Sanborn; J E Sippel
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

10.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307
View more
  5 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Meningococcal glycoconjugate vaccines.

Authors:  Roberto Gasparini; Donatella Panatto
Journal:  Hum Vaccin       Date:  2011-02-01

3.  Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  A E Platonov; V B Beloborodov; L I Pavlova; I V Vershinina; H Käyhty
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Adverse reactions associated with simultaneous administration of multiple vaccines to travelers.

Authors:  C Falvo; H Horowitz
Journal:  J Gen Intern Med       Date:  1994-05       Impact factor: 5.128

Review 5.  Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.

Authors:  Janette M Harro; Brian M Peters; Graeme A O'May; Nathan Archer; Patrick Kerns; Ranjani Prabhakara; Mark E Shirtliff
Journal:  FEMS Immunol Med Microbiol       Date:  2010-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.